Navigation Links
Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
Date:10/24/2009

NEW YORK, Oct. 23 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; Frankfort Borse: PBO) has announced that it will ultimately receive at least $3.3 million pursuant to the license agreement contemplated by the previously announced non-binding letter of intent with Biotechnology Consulting Poland Sp. z.o.o. with respect to its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) development work, clinical trials and ultimately, commercialization in the European market.

"We are pleased that the relationship with Biotechnology Consulting Poland to be finalized in a license agreement expected before the end of 2009 will allow Pulmo BioTech to bring PulmoBind(TM) to the whole of the European Union and European Economic Area. Under the contemplated license agreement, Pulmo BioTech will be providing all of the technical resources to enable this to happen, and in return Biotechnology Consulting Poland will be providing a substantial cash element to Pulmo BioTech. Biotechnology Consulting Poland will license the technology to enable them to carry out all of the trials necessary to gain European Approval for PulmoBind(TM) with the intention that they will then commercialize PulmoBind across Europe. By following this parallel approach with Pulmo BioTech concentrating on the North American market and Biotechnology Consulting Poland having responsibility for Europe, we expect to minimize the time required to complete trials and, provided that regulatory approval is ultimately obtained, to gain maximum sales for PulmoBind(TM) across both these major markets to the benefit of our shareholders and the medical community." - Garry McCann, CEO Pulmo BioTech Inc.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowl
'/>"/>

SOURCE Pulmo BioTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System
2. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
3. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
4. Biomodels Expands Efforts in Cancer Supportive Care, Pulmonary Fibrosis; Preclinical Research Organization Names Dr. Stephen T. Sonis as Partner
5. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
6. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
7. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
8. University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System
9. Pulmo BioTech Inc. Announces Paper to be Presented at Symposium
10. FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
11. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... DIEGO , Dec. 15, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... the industry and collaborators of its exVive3D TM ... made widely available in full commercial release on ... the field, resulting in several awards for innovation. ...
(Date:12/15/2014)... Denmark , Dec. 15, 2014  Ascendis ... innovative TransCon technology to address significant unmet medical ... its ongoing Phase 2 pediatric study to evaluate ... hormone deficiency, or GHD.  This interim analysis consists ... anticipated total enrollment in the study, completing all ...
(Date:12/13/2014)... Rockville, Maryland (PRWEB) December 12, 2014 ... Maryland, today announced its new name: Therabron Therapeutics ... words therapy and bronchioles (a type of structure in ... incorporating the company’s mission to develop novel protein therapeutics ... board of directors decided to change the name to ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... of person to staff customer support centers. These specialists must ... of a complicated computer system, and then be able to ... Finding these very talented people is not an easy task, ... high degree of technical aptitude. But there is more to ...
... of Fiserv, Inc. has announced the launch ... self-funded health care market. , , Fiserv Health ... administration services for self-funded medical, dental, vision and disability ... now has an integrated suite of medical management programs ...
... named to the top five in the "specialty niche" ... KLAS , a provider of healthcare information technology (HIT) ... score for all time and attendance system vendors scoring ... Performance award. , , KLAS provides the ...
Cached Biology Technology:Hope For Some U.S. Tech Workers 2Hope For Some U.S. Tech Workers 3Fiserv Launches Avidyn Health to Target Healthcare Costs 2API Receives Top 5 Recognition in "Best In KLAS" Awards 2
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
... study to conserve and restore endangered horse mussel reefs ... University,s marine research and outreach centre in Portaferry in ... Biological Sciences, will provide scientific and technological research to ... restore it. Horse mussel reefs are important to ...
... one of the major threats to biodiversity and in ... human health. For their effective management it is important ... highest risk of being invaded. The first map ... Union was published in the Wiley-Blackwell journal Diversity ...
... Amsterdam, The Netherlands, January 22, 2009 A growing ... to delay age-related cognitive decline, including in some cases ... published in the January 2009 issue of the ... PhD, of the Center for Cellular Neurobiology; Neurodegeneration Research ...
Cached Biology News:Queen's University Belfast works to save Strangford horse mussels 2
...
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Biology Products: